Search clinical trials for: ALXN1820 IV

Total 3268 results

Alexion Pharmaceuticals, Inc.
Syneos Health

Completed

Study of ALXN1820 in Healthy Adult Participants

Healthy

Australia, United Kingdom
Alexion Pharmaceuticals

Completed

Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects

Healthy

United Kingdom
Alexion

Active, not recruiting

Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease (PHOENIX)

Sickle Cell Disease (SCD)

United States, France
Alexion

Completed

A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants

Healthy

United Kingdom
Alexion Pharmaceuticals, Inc.

Completed

Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants

Wilson Disease

United Kingdom
Alexion Pharmaceuticals

Completed

Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

Wilson Disease

United States, Germany, Austria, Poland, United Kingdom
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP (MULBERRY)

Hypophosphatasia

Israel, Korea, Republic of, Taiwan, Sweden, Germany, Italy, Turkey, China, Poland, United States, France, Australia, Thailand, United Kingdom, Mexico, Vietnam, Argentina, Belgium, Brazil, Canada, Spain
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa (HICKORY)

Hypophosphatasia

Italy, Spain, Israel, Korea, Republic of, Belgium, Germany, United States, China, France, Taiwan, Austria, Japan, India, Australia, Argentina, Poland, Turkey, Brazil, Canada, Thailand, United Kingdom, Slovakia, Czechia
Alexion Pharmaceuticals, Inc.

Terminated

A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants

Healthy

United Kingdom
Alexion Pharmaceuticals, Inc.

Completed

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants

Healthy Participants

New Zealand
Alexion Pharmaceuticals

Withdrawn

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States
Alexion Pharmaceuticals

Terminated

A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

Warm Autoimmune Hemolytic Anemia

United States, Jordan
Alexion Pharmaceuticals

Terminated

A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

Pemphigus | Pemphigus Vulgaris | Pemphigus Foliaceus

United States
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa (CHESTNUT)

Hypophosphatasia

Australia, United States, Japan, Germany, Turkey, Italy, India, France, United Kingdom, Argentina, Canada
Alexion Pharmaceuticals
Syneos Health

Terminated

A Study of ALXN1830 in Healthy Adult Participants

Healthy

New Zealand
Alexion

Completed

Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

Proteinuria

Korea, Republic of
Alexion Pharmaceuticals, Inc.
Parexel

Recruiting

A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants

Healthy Adult Participants

Canada, United Kingdom
Alexion

Completed

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants

Healthy

United Kingdom
Alexion Pharmaceuticals, Inc.

Recruiting

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

China, United States, Spain, United Kingdom, Korea, Republic of, Germany, Italy, Japan, Brazil, France, Netherlands, Taiwan, Turkey, Israel, Poland, Austria, Denmark, Portugal, Canada, Serbia, Argentina, Switzerland
Alexion Pharmaceuticals

Withdrawn

ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

United States
Alexion Pharmaceuticals

Terminated

Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Czech Republic, Italy, Poland, United Kingdom
Alexion Pharmaceuticals

Completed

Copper Balance in Healthy Participants Administered ALXN1840

Healthy

United Kingdom
Alexion Pharmaceuticals, Inc.

Completed

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

Hypophosphatasia

United States
Alexion

Withdrawn

Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

United States
Alexion

Completed

Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840

Wilson Disease

United States, New Zealand, United Kingdom
Alexion Pharmaceuticals, Inc.

Terminated

Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

Wilson Disease

Spain, Korea, Republic of, France, Germany, Japan, Australia, Poland, United Kingdom
Alexion Pharmaceuticals, Inc.

Recruiting

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM (DepleTTR-CM)

Transthyretin Amyloid Cardiomyopathy

United States, Spain, United Kingdom, Norway, Israel, China, Korea, Republic of, France, Germany, Italy, Japan, Belgium, Australia, Argentina, Austria, Taiwan, Switzerland, Canada, Sweden, Poland, Denmark, Turkey, Brazil, Netherlands, G... and more
Taipei City Hospital

Not yet recruiting

TCHCCT-Zhong-Xing-Emergency-Department Ultrasound With IV Contrast in Acute Flank Pain

Acute Flank Pain

Taiwan
Eli Lilly and Company

Completed

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

Psoriasis

United States
Healthgen Biotechnology Corp.

Completed

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

Ascites Hepatic

United States
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
Kyowa Kirin Co., Ltd.

Terminated

Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis

Atopic Dermatitis

Japan
Asir John Samuel
Maharishi Markendeswar University (Deemed to be University)

Recruiting

Class IV Laser Therapy on Ejection Fraction, Cardio Biomarkers and Functional Outcomes

Acute Coronary Syndrome

India
Eli Lilly and Company

Completed

A Study of LY3002813 in Participants With Alzheimer's Disease

Alzheimer Disease

United States, Japan
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

Infections, Bacterial

United States
Military Institute od Medicine National Research...
ABM Industries

Recruiting

Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19. (COVMENT)

Nervous System Diseases

Poland
C. R. Bard

Completed

AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use

Vascular Access Complication

United States
Eli Lilly and Company

Completed

A Study of LY3475766 in Healthy Participants

Dyslipidemias

United States
Wockhardt

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

Bioavailability

United States
Prometheus Biosciences, Inc., a subsidiary of Merck...
Altasciences Company Inc.

Completed

Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

Healthy

United States
Oculis
Neurotrials

Recruiting

OCS-05 in Patients With Acute Optic Neuritis (ACUITY)

Optic Neuritis | Optic; Neuritis, With Demyelination

France
Gmax Biopharm LLC.

Recruiting

A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, China
Flame Biosciences

Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer | Solid Tumor | Pancreas Cancer
Universitaire Ziekenhuizen KU Leuven
BEDAL; Remedus

Terminated

Impact of Availability of Showerpatch for Patients With Intravenous Catheters (ISIC)

Neoplasms | Cystic Fibrosis | Pulmonary Hypertension

Belgium
Qilu Pharmaceutical Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD)

Healthy

China
Bayer

Recruiting

A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)

Pulmonary Hypertension Due to Left Heart Disease

Germany
Eli Lilly and Company

Completed

A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3361237 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Terminated

A Study of LY3478006 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3375880 in Healthy Participants

Healthy

United States

Search clinical trials for: ALXN1820 IV

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations